Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression

Abstract excerpt

EZH2 is frequently overexpressed in glioblastoma (GBM), suggesting an oncogenic function that could be a target for therapeutic intervention. However, reduced EZH2 activity can also promote tumorigenesis, leading to concerns about the use of EZH2 inhibitors. Here, we provide further insight about the effects of prolonged Ezh2 inhibition in glioblastoma using preclinical mouse models and primary tumor-derived...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Epigenetics and DNA Methylation
• Share to Glioma Diagnosis and Treatment
• Share to MicroRNA in disease regulation